Phase 2 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to sign the consent form and follow the study schedule and requirements.
- People aged 18 or older at the time of signing the consent form.
- People who have at least one tumour or lesion that can be measured on a scan, according to standard measurement guidelines (called RECIST v1.1).
- People who are reasonably active and able to care for themselves, with only mild limitations on daily activities (this is measured using a standard scale called ECOG, with a score of 0 or 1).
- People with a life expectancy of at least 3 months.
Who may not be able to join:
- People who have cancer that has spread to the membranes surrounding the brain or spinal cord.
- People who have uncontrolled fluid build-up around the lungs, heart, or in the abdomen that requires draining every two weeks or more often.
- People who have taken part in another clinical trial and received an experimental drug within the 4 weeks before starting this study.
- People who still have side effects from previous cancer treatment that have not improved to a mild level (with some exceptions, such as hair loss or certain other mild side effects that the trial doctor considers low risk).
- People who have a significant eye condition affecting the cornea or retina — including but not limited to certain types of keratopathy, corneal injury, inflammation, ulceration, or eye surface inflammation — as assessed by the trial doctor (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 0086-21-50895559
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose Escalation Phase:Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs); Dose Escalation Phase:Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of 3H-10000; Dose Escalation Phase:The recommended Phase 2 dose (RP2D) of 3H-10000; Efficacy Expansion Phase:Overall Response Rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.